---
title: Transcutaneous Bilirubinometry in Neonates With the Bilicare System
nct_id: NCT02445755
overall_status: COMPLETED
sponsor: Stanford University
study_type: OBSERVATIONAL
primary_condition: Transcutaneous Bilirubinometry
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02445755.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02445755"
ct_last_update_post_date: 2015-06-04
last_seen_at: "2026-05-12T06:44:41.413Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Transcutaneous Bilirubinometry in Neonates With the Bilicare System

**NCT ID:** [NCT02445755](https://clinicaltrials.gov/study/NCT02445755)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 113
- **Lead Sponsor:** Stanford University
- **Conditions:** Transcutaneous Bilirubinometry
- **Start Date:** 2014-06
- **Completion Date:** 2015-05
- **CT.gov Last Update:** 2015-06-04

## Brief Summary

The purpose of this study is to test the performance of a new transcutaneous ("measured through skin") bilirubin device (BiliCare™) to measure bilirubin levels. The investigators plan to evaluate the clinical performance of this device as a point of care test. If the investigators can validate the BiliCare™ with bilirubin from your baby's blood they could verify a non-invasive alternative for measuring bilirubin.

## Eligibility

- **Minimum age:** 35 Weeks
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Parental informed consent
2. Male and female newborns with a GA ≥ 35 wks
3. Enrollment at age \> 6 hrs until neonatal discharge
4. Pre-phototherapy

Exclusion Criteria:

1. Infants requiring respiratory assistance (such as mechanical ventilation)
2. Severe or life-threatening congenital anomalies
3. Hematomas at the point of measurement on both ears
4. Neonates undergone blood transfusion
```

## Primary Outcomes

- **In This Study, the Investigators Plan to Test the Performance of a Novel Transcutaneous Device (BiliCareTM) to Screen for Bilirubin Levels at Postnatal Age of 12 to 48 Hours.** _(time frame: 12 to 48 hours)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02445755.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02445755*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*